Product Information
Aquaporin-4 (AQP4) Antibody - ELISA
EA111/96
Enzyme Immuno Assay
for the quantitative determination of
autoantibodies to aquaporin-4 (AQP4) in serum
12x8 Determinations
microtiter plate
Neurology, Immunology, Autoimmune Diseases
see Instructions for Use
Negative < 3.0 U/mL; Positive ≥ 3.0 U/mL
99% for n = 358 healthy blood donors
77% for n = 62 patients with NMO or NMO spectrum disorder (NMOSD)
Reliable and convenient method to measure AQP4 autoantibodies, which are a specific marker for Neuromyelitis Optica (NMO), also known as Devic’s syndrome.
Measurement of AQP4 autoantibodies can be of considerable value in distinguishing NMO from Multiple Sclerosis when full clinical features may not be apparent and early intervention may prevent or delay disability. Total assay time is ~3 hours only. The ELISA method is an easy assay format for use in the routine clinical laboratory and suitable for automated systems.
Es gelten folgende Patente: Europäisches Patent EP 1 700 120 B1, US Patente US 7,101,679 und US 7,947,254 B2 und US 8,889,102 B2, chinesisches Patent ZL200480040851.3 und japanisches Patent 4538464.